While p16 (CDKN2A) gene deletion and inactivation of myc-associated protein (MAX) are found to be common genetic aberrations in GIST progression [8, 9], a better understanding of the molecular mechanisms responsible for GIST aggressiveness may identify clinical biomarkers or new therapeutic targets. Here, MYCBP2 is linked to gastrointestinal stromal tumor.